Literature DB >> 17926084

Accelerated thrombotic occlusion of a medium-sized coronary aneurysm in Kawasaki disease by the inhibitory effect of ibuprofen on aspirin.

Sejung Sohn1, Kihwan Kwon.   

Abstract

The fate of coronary artery aneurysms (CAAs) caused by Kawasaki disease depends mainly on their initial size and shape. Small to medium-sized CAAs are known to regress to normal size or decrease in size, with a good outcome. A patient with Kawasaki disease is reported who had a medium-sized CAA prematurely occluded with thrombi during regression, resulting in myocardial ischemia. This event was probably due to simultaneous use of aspirin and ibuprofen. Thus, the concomitant use of ibuprofen should be avoided when aspirin is given as an antiplatelet agent because ibuprofen blocks the platelet inhibition induced by aspirin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17926084     DOI: 10.1007/s00246-007-9123-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  7 in total

1.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Authors:  F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

2.  Fate of coronary arterial aneurysms in Kawasaki disease.

Authors:  A Suzuki; T Kamiya; Y Arakaki; Y Kinoshita; K Kimura
Journal:  Am J Cardiol       Date:  1994-10-15       Impact factor: 2.778

3.  Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease.

Authors:  S P Etheridge; L Y Tani; L L Minich; J R Revenaugh
Journal:  Cathet Cardiovasc Diagn       Date:  1998-11

4.  Clinical significance of morphologic classification of coronary arterial segmental stenosis due to Kawasaki disease.

Authors:  A Suzuki; T Kamiya; Y Ono; Y Kinoshita; S Kawamura; K Kimura
Journal:  Am J Cardiol       Date:  1993-05-15       Impact factor: 2.778

5.  Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease.

Authors:  H Nakano; K Ueda; A Saito; K Nojima
Journal:  Am J Cardiol       Date:  1985-11-15       Impact factor: 2.778

6.  Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study.

Authors:  H Kato; E Ichinose; F Yoshioka; T Takechi; S Matsunaga; K Suzuki; N Rikitake
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

7.  Regression of coronary aneurysms in patients with Kawasaki syndrome.

Authors:  M Takahashi; W Mason; A B Lewis
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

  7 in total
  7 in total

1.  Deterioration of cutaneous microcirculatory status of Kawasaki disease.

Authors:  Ming-Yii Huang; Joh-Jong Huang; Teh-Yang Huang; Monesha Gupta-Malhotra; Fei-Kai Syu
Journal:  Clin Rheumatol       Date:  2012-02-04       Impact factor: 2.980

Review 2.  Delayed diagnosis of Kawasaki syndrome and thrombosis of a medium-sized aneurysm of the anterior descending coronary artery: case report and literature review.

Authors:  Gabriella De Rosa; Maria Giuseppina Cefalo; Riccardo Marano; Marco Piastra; Angelica Bibiana Delogu; Donato Rigante
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631

3.  Successful emergent coronary thrombolysis in a neonate with Kawasaki's disease.

Authors:  Vijay R Karia; George C Hescock; Abraham Gedalia; Abraham Gedelia; Nancy Ross-Ascuitto
Journal:  Pediatr Cardiol       Date:  2010-08-27       Impact factor: 1.655

4.  Intravenous Immunoglobulin Nonresponse in Pediatric Patients Treated for Kawasaki Disease at a US Hospital.

Authors:  Lauryn Smelser; Jennifer Vejzovic; Emma Johnson; Jordan Schultz; Kelly E Wood
Journal:  J Pediatr Pharmacol Ther       Date:  2022-02-09

5.  Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers.

Authors:  J N Suresh Kumar; Prameela Devi; Lakshmi Narasu; Ramesh Mullangi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

6.  Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease.

Authors:  Lei Pi; Di Che; Haifeng Long; Zhenzhen Fang; Jiawen Li; Shuyi Lin; Yunfeng Liu; Meiai Li; Lijuan Bao; Wenli Li; Yuan Zhang; Qiulian Deng; Techang Liu; Li Zhang; Xiaoqiong Gu
Journal:  Drug Des Devel Ther       Date:  2018-05-23       Impact factor: 4.162

7.  ABCC4 Variants Modify Susceptibility to Kawasaki Disease in a Southern Chinese Population.

Authors:  Di Che; Lei Pi; Zhenzhen Fang; Yufen Xu; Minmin Cai; Lanyan Fu; Huazhong Zhou; Li Zhang; Xiaoqiong Gu
Journal:  Dis Markers       Date:  2018-09-30       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.